GlobeNewswire

Cloudian and Storage Made Easy Launch GDPR-Ready Enterprise File Sync-and-Share Solution

Dela

Ensures compliance by controlling user data location and access, while monitoring for use of regulated personal data

LONDON and SAN MATEO, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Cloudian® and Storage Made Easy® (SME) have launched a General Data Protection Regulation (GDPR)-ready, enterprise-wide file sync-and-share solution, designed to eliminate the compliance exposure of external cloud-based file sharing services where personal data or company confidential information may reside outside the direct control of the IT organization.

The combined solution includes on-premises storage and GDPR-ready collaboration software with access controls and content indexing to continuously monitor for the use of regulated personal data, recognising more than 60 data types including credit card, passport and social security numbers.

Unlike most cloud-based file sharing services, the Cloudian/SME solution lets IT managers control their data's physical location and manage access permissions via existing company authentication frameworks such as Active Directory and LDAP. The solution also provides secure file sharing controls such as password-protected links, configurable download limits, and expiration dates after which links will be disabled automatically. All data accesses are logged, maintaining an audit trail for compliance.   

"With GDPR now in effect, organizations must implement tight controls over data location and usage -- particularly when personal data is at stake -- requirements that most cloud-based services do not meet," said Michael Tso, CEO of Cloudian. "The Cloudian/SME solution gives IT managers peace-of-mind, with end-to-end control of data location and access, and a continuous view of where files are stored, how they are shared, and where personal data is employed."

Compatible with Windows, Mac, Linux, iOS and Android platforms, the solution includes configurable synchronization options that let users control where data is replicated, and integration with Microsoft Office and email applications that allow users to securely access and share files.

"Users are going to share information, but that does not mean that IT managers need to lose control. The challenge is to provide easy-to-use file sharing that boosts productivity while ensuring that sensitive information remains secure," said Jim Liddle, CEO of Storage Made Easy. "Cloudian and SME together provide the best of both worlds, combining the simplicity of a cloud-like solution, the security of on-premises storage, and the comprehensive compliance enforcement afforded by our GDPR-ready feature set."

Multiple privacy regulations mandate strict controls on data handling, including the EU General Data Protection Regulation and the California Consumer Privacy Act of 2018. These require that companies collecting personal data - which includes a wide range of information such as names, identification numbers, location data or online identifiers - both protect the data and delete it if requested. Compliance requires tight controls on how such information is stored and used.

"Our customers needed a turnkey solution to simplify compliance, and we responded with CloudDrive, a Cloudian and Storage Made Easy-based solution that provides GDPR-aligned file sync-and-share service for the enterprise," said Julian Box, CEO at Calligo. "With Cloudian storage and SME software, our customers get easy-to-use file sharing and powerful data management tools that keep IT in control, making compliance one less thing to worry about."

About Store Made Easy
Storage Made Easy provides a multi-cloud data management and data protection product called the Enterprise File Fabric(TM) that unifies on-premises and on-cloud company storage assets, in addition to standalone products that bridge desktop and cloud, such as operating system-native cloud drives and cloud explorer applications. The company is backed by one of the largest alternative asset managers in addition to entrepreneurs in the London market insurance industry, who have previously successfully sold their company to a listed peer.

Storage Made Easy is the trading name of Vehera LTD. Follow us on Twitter @SMEStorage and visit us at www.StorageMadeEasy.com to learn more.

About Cloudian
Cloudian turns information into insight with an infinitely scalable platform that consolidates, manages and protects enterprise data. Cloudian data management solutions bring cloud technology and economics to the data centre with uncompromising data durability, intuitive management tools, and the industry's most compatible S3 API. Cloudian and its ecosystem partners help Global 1000 customers simplify unstructured data management today, while preparing for the data demands of AI and machine learning tomorrow.

Join us on LinkedIn, follow us on Twitter (@CloudianStorage) and Facebook, or visit us at www.cloudian.com.

Media Contacts

Emily Gallagher
Touchdown PR 
Cloudian@touchdownpr.com
+44 (0)1252 717040

Alex Mercurio
10Fold Communications 
cloudian@10fold.com 
949-940-5656




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cloudian via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum